Vanguard Group Inc Cyclo Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 446,573 shares of CYTH stock, worth $334,929. This represents 0.0% of its overall portfolio holdings.
Number of Shares
446,573
Previous 396,658
12.58%
Holding current value
$334,929
Previous $551,000
2.9%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CYTH
# of Institutions
23Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA817KShares$612,9520.39% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$360,53172.16% of portfolio
-
Geode Capital Management, LLC Boston, MA175KShares$131,5630.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$82,517100.0% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$44,6320.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.33M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...